J G Nutt

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
    J G Nutt
    Oregon Health and Science University, Portland 97201 3098, USA
    Neurology 60:69-73. 2003
  2. ncbi request reprint Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 31:243-68. 2004
  3. ncbi request reprint Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements
    John G Nutt
    Neurology 66:1611-2; author reply 1611-2. 2006
  4. pmc Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease
    Erika Franzén
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    Exp Neurol 219:430-8. 2009
  5. doi request reprint Mobility, mood and site of care impact health related quality of life in Parkinson's disease
    J G Nutt
    Oregon Health and Science University, USA Electronic address
    Parkinsonism Relat Disord 20:274-9. 2014
  6. pmc Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism
    Parvoneh Poorkaj
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    BMC Neurol 5:4. 2005
  7. ncbi request reprint Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD
    J G Nutt
    Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Neurology 54:247-50. 2000
  8. ncbi request reprint Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
    John G Nutt
    Parkinson Center of Oregon, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Mov Disord 22:1-9. 2007
  9. ncbi request reprint The dopamine transporter: importance in Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Ann Neurol 55:766-73. 2004
  10. doi request reprint Pharmacokinetics and pharmacodynamics of levodopa
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Parkinson Disease Research, Education and Clinical Center, Portland VA, Oregon, USA
    Mov Disord 23:S580-4. 2008

Detail Information

Publications63

  1. ncbi request reprint Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
    J G Nutt
    Oregon Health and Science University, Portland 97201 3098, USA
    Neurology 60:69-73. 2003
    ..To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD...
  2. ncbi request reprint Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 31:243-68. 2004
    ..The maximum levodopa induced response after the drug holiday is a result of lowered baseline tapping due to the loss of long-duration response and not due to a change in levodopa pharmacokinetics or pharmacodynamics...
  3. ncbi request reprint Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements
    John G Nutt
    Neurology 66:1611-2; author reply 1611-2. 2006
  4. pmc Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease
    Erika Franzén
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    Exp Neurol 219:430-8. 2009
    ..55, p<0.05). Our results suggest that neck tone plays a significant role in functional mobility and that abnormally high postural tone may be an important contributor to balance and mobility disorders in individuals with PD...
  5. doi request reprint Mobility, mood and site of care impact health related quality of life in Parkinson's disease
    J G Nutt
    Oregon Health and Science University, USA Electronic address
    Parkinsonism Relat Disord 20:274-9. 2014
    ..Examine the correlates of Health Related Quality of Life (HRQL) in a large cohort of Parkinson's disease (PD) patients from National Parkinson Foundation (NPF) Centers of Excellence (COEs)...
  6. pmc Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism
    Parvoneh Poorkaj
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    BMC Neurol 5:4. 2005
    ..A subset of familial PD exhibits anticipation, the cause of which is unknown. The aim of this study was to determine if anticipation was due to parkin mutation dosage...
  7. ncbi request reprint Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD
    J G Nutt
    Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Neurology 54:247-50. 2000
    ..Apomorphine maintained the LDR to the extent that it kept the subjects "on" during the day. This observation suggests that the LDR can be a postsynaptic effect, independent of dopamine storage...
  8. ncbi request reprint Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
    John G Nutt
    Parkinson Center of Oregon, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Mov Disord 22:1-9. 2007
    ..Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized...
  9. ncbi request reprint The dopamine transporter: importance in Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Ann Neurol 55:766-73. 2004
    ..These observations indicate that the residual DAT is functional in PD and is a potential target for symptomatic therapy of PD...
  10. doi request reprint Pharmacokinetics and pharmacodynamics of levodopa
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Parkinson Disease Research, Education and Clinical Center, Portland VA, Oregon, USA
    Mov Disord 23:S580-4. 2008
    ..Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations...
  11. pmc Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Mov Disord 23:1860-6. 2008
    ..However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects...
  12. ncbi request reprint Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial
    John G Nutt
    Department of Neurology, and Public Health and Preventative Medicine, Division of Biostatistics, Oregon Health and Science University, Portland, OR 97239, USA
    Arch Neurol 64:319-23. 2007
    ....
  13. ncbi request reprint Clinical practice. Diagnosis and initial management of Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland 97239, USA
    N Engl J Med 353:1021-7. 2005
  14. pmc Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Neurology 74:1191-7. 2010
    ....
  15. ncbi request reprint Evolution of the response to levodopa during the first 4 years of therapy
    John G Nutt
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201 3098, USA
    Ann Neurol 51:686-93. 2002
    ..Improving the baseline or practical-off motor function to reduce the magnitude of the short-duration response may be a strategy to treat fluctuations...
  16. doi request reprint Milestones in gait, balance, and falling
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Mov Disord 26:1166-74. 2011
    ....
  17. ncbi request reprint Interactions between deep brain stimulation and levodopa in Parkinson's disease
    J G Nutt
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Neurology 57:1835-42. 2001
    ..To quantify the effects of deep brain stimulation (DBS) of globus pallidus interna (GPi) and subthalamic nucleus (STN) on motor fluctuations and dyskinesia in PD and to determine how the response to levodopa was modified by DBS...
  18. ncbi request reprint Motor fluctuations and dyskinesia in Parkinson's disease
    J G Nutt
    Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland, OR 97201 3098, USA
    Parkinsonism Relat Disord 8:101-8. 2001
    ..A variety of clinical strategies may reduce the unpredictability of motor fluctuations and reduce their impact. Prevention of these complications remains an elusive goal...
  19. ncbi request reprint DBS and diathermy interaction induces severe CNS damage
    J G Nutt
    Department of Neurology, Oregon Health Sciences University, Portland 97201 3098, USA
    Neurology 56:1384-6. 2001
    ..Pulse-modulated radiofrequency diathermy treatment to the maxilla produced permanent diencephalic and brainstem lesions and a vegetative state in a patient with PD with implanted subthalamic electrodes for deep brain stimulation...
  20. ncbi request reprint Freezing of gait: moving forward on a mysterious clinical phenomenon
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Lancet Neurol 10:734-44. 2011
    ..A better understanding of the phenomenon is needed to aid the development of effective therapeutic strategies...
  21. ncbi request reprint Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study
    R Camicioli
    Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
    Clin Neuropharmacol 24:208-13. 2001
    ..Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations...
  22. ncbi request reprint Direction-specific postural instability in subjects with Parkinson's disease
    Fay B Horak
    Neurological Sciences Institute, Oregon Health and Science University, Portland, OR 97006 3499, USA
    Exp Neurol 193:504-21. 2005
    ..These results suggest that the basal ganglia, in addition to regulating muscle tone and energizing postural muscle activation, also are critical for adapting postural response patterns for specific biomechanical conditions...
  23. pmc A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD
    R J St George
    Department of Neurology, Oregon Health and Sciences University, 505 NW 185 Avenue, Beaverton, OR 97006, USA
    Neurology 75:1292-9. 2010
    ..This prompted us to conduct the first meta-regression of long-term studies of bilateral DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi)...
  24. doi request reprint Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials
    Steven A Gunzler
    Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, OR, USA
    Clin Neuropharmacol 32:97-102. 2009
    ..To explore foot-tapping rate as a reliable and a valid measure of motor function in Parkinson disease (PD)...
  25. ncbi request reprint Response to levodopa treatment in dopa-responsive dystonia
    J G Nutt
    Department of Neurology, OP 32, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201-3098, USA
    Arch Neurol 58:905-10. 2001
    ..The decline in motor function in DRD on withdrawal of long-term levodopa therapy resembles that in Parkinson disease, suggesting that a long-duration response, if it exists in DRD, is unrelated to dopamine storage...
  26. ncbi request reprint Postural muscle responses to multidirectional translations in patients with Parkinson's disease
    Diana Dimitrova
    Neurological Sciences Institute, Oregon Health and Science University, Beaverton, Oregon 97006 3499, USA
    J Neurophysiol 91:489-501. 2004
    ..These results are consistent with the hypothesis that PD results in an inability to shape the pattern and magnitude of postural muscle responses for changes in perturbation direction and in stance position...
  27. pmc Objective measurement of dyskinesia in Parkinson's disease using a force plate
    Kathryn A Chung
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    Mov Disord 25:602-8. 2010
    ..Sensitivity to changes in LID was initially demonstrated but should be repeated. Thus, CoP recordings on a force plate can objectively quantify LID in PD and may be very useful in clinical trials or other investigations of dyskinesia...
  28. ncbi request reprint Joubert syndrome surviving to adulthood associated with a progressive movement disorder
    Steven A Gunzler
    Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, Oregon, USA
    Mov Disord 22:262-5. 2007
    ..This case demonstrates that a patient with Joubert syndrome may survive into adulthood and present as a chronic neurologic disorder with subacute extrapyramidal signs...
  29. pmc Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease
    Matthew A Brodsky
    Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, OP 32, Portland, OR 97239
    Arch Neurol 67:27-32. 2010
    ..Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood...
  30. ncbi request reprint Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice
    Steven A Gunzler
    Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, OR, USA
    Neurosci Lett 428:64-7. 2007
    ..Our results suggest that low doses of apomorphine can initially depress locomotion and subsequently stimulate locomotion, in a manner similar to what is seen in Parkinson's disease patients...
  31. pmc The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease
    Cris Zampieri
    Oregon Health and Science University, Department of Neurology, 505 NW 185th Avenue, Portland, OR 97006, USA
    J Neurol Neurosurg Psychiatry 81:171-6. 2010
    ..Thus, the iTUG test is sensitive to untreated PD and could potentially detect progression of PD and response to symptomatic and disease-modifying treatments...
  32. ncbi request reprint Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study
    Jau Shin Lou
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    Clin Neuropharmacol 32:305-10. 2009
    ..Fatigue is a major nonmotor symptom in Parkinson disease(PD). It is associated with reduced activity and lower quality of life...
  33. pmc Knee trembling during freezing of gait represents multiple anticipatory postural adjustments
    Jesse V Jacobs
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Exp Neurol 215:334-41. 2009
    ..These observations suggest that multiple APAs produce the knee trembling commonly associated with FoG and that FoG associated with a forward loss of balance is caused by an inability to couple a normal APA to the stepping motor pattern...
  34. ncbi request reprint Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201 3098, USA
    Exp Neurol 184:9-13. 2003
  35. ncbi request reprint Short-term paroxetine treatment does not alter the motor response to levodopa in PD
    Kathryn A Chung
    Oregon Health and Science University, Portland, OR 97239 3098, USA
    Neurology 64:1797-8. 2005
    ..Paroxetine did not affect tapping scores or dyskinesia. Baseline walking speed (preinfusion) increased on paroxetine, often associated with an increased subjective perception of worsened balance...
  36. ncbi request reprint Neuroimmunophilin ligands in the treatment of Parkinson's disease
    Bruce G Gold
    Center for Research on Occupational and Environmental Toxicology, Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97201 3098, USA
    Curr Opin Pharmacol 2:82-6. 2002
    ..To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing...
  37. pmc Preparation for compensatory forward stepping in Parkinson's disease
    Laurie A King
    Department of Neurology, Oregon Health and Science University, Beaverton, OR, USA
    Arch Phys Med Rehabil 91:1332-8. 2010
    ..To characterize preparation for compensatory stepping in people with Parkinson's disease (PD) compared with healthy control subjects, and to determine whether levodopa medication improves preparation or the execution phases of the step...
  38. ncbi request reprint OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease
    Matthew A Brodsky
    Department of Neurology, Oregon Health and Science University, and Parkinson s Disease Research, Education and Clinical Care Center, Portland VA Medical Center, Portland, Oregon, USA
    Mov Disord 21:1487-90. 2006
    ..When the stimulators were turned back on, the dyskinesias soon resolved. This article is a first report of a unique pattern of rebound-type dyskinesia that occurred in the off medication state produced by stopping STN DBS...
  39. pmc Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
    Kathryn A Chung
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    Neurology 75:1263-9. 2010
    ..To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability...
  40. pmc Multiple balance tests improve the assessment of postural stability in subjects with Parkinson's disease
    J V Jacobs
    Neurological Sciences Institute, Oregon Health and Science University, Portland, OR, USA
    J Neurol Neurosurg Psychiatry 77:322-6. 2006
    ..We sought to determine whether combining the pull test, the one-leg stance test, the functional reach test, and UPDRS items 27-29 (arise from chair, posture, and gait) predicts balance confidence and falling better than any test alone...
  41. pmc Can stooped posture explain multidirectional postural instability in patients with Parkinson's disease?
    Jesse V Jacobs
    Neurological Sciences Institute, Oregon Health and Science University, 505 NW 185th Avenue, Beaverton, Portland, OR 97006 3499, USA
    Exp Brain Res 166:78-88. 2005
    ..Upright and stooped control subjects never fell during the trials, whereas PD subjects fell in 16% of the trials. We conclude that stooped posture is a destabilizing posture, but it does not account for abnormal postural responses in PD...
  42. pmc Analyzing 180 degrees turns using an inertial system reveals early signs of progression of Parkinson's disease
    Arash Salarian
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    Conf Proc IEEE Eng Med Biol Soc 2009:224-7. 2009
    ..85). Turning duration also showed a significant Group *Time interaction (p<0.03) during the longitudinal study highlighting early signs of the progression of the disease...
  43. ncbi request reprint Parkinson's disease
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
    Lancet 363:1783-93. 2004
    ..This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis...
  44. ncbi request reprint An alternative clinical postural stability test for patients with Parkinson's disease
    Jesse V Jacobs
    Neurological Sciences Institute, Oregon Health and Science University, Beaverton, OR 97006 3499, USA
    J Neurol 253:1404-13. 2006
    ..The Push and Release Test correlated better with self-reported falls. Therefore, the Push and Release Test provided a more sensitive and consistent test of postural stability than the Pull Test...
  45. doi request reprint Treatment of Parkinson's disease with trophic factors
    Amie L Peterson
    Parkinsons Disease Research, Educational and Clinical Center, Portland Veteran s Administration Medical Center, Portland, Oregon 97239, USA
    Neurotherapeutics 5:270-80. 2008
    ..Utility for such compounds in patients with Parkinson's disease and ongoing loss of dopaminergic neurons remains to be proven...
  46. ncbi request reprint Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)
    Sarah Furtado
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mov Disord 19:622-9. 2004
    ..This review emphasizes the importance of testing for SCA2 in patients with parkinsonism and a family history of neurodegenerative disorders. Testing for SCA2 is also important in studies of inherited parkinsonism...
  47. ncbi request reprint Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:459-84. 2005
    ....
  48. ncbi request reprint Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
    Anthony E Lang
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Ann Neurol 59:459-66. 2006
    ..This randomized controlled clinical trial was designed to confirm initial clinical benefits observed in a small, open-label trial using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin)...
  49. ncbi request reprint Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments
    Nicholas H G Holford
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 33:281-311. 2006
    ..We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression...
  50. ncbi request reprint Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:307-31. 2005
    ..Variability in levodopa pharmacokinetic parameters (particularly V1) may result in variability in plasma levodopa concentrations that could contribute to fluctuations in motor response...
  51. ncbi request reprint Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    Pharm Res 24:791-802. 2007
    ..To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial...
  52. pmc Disease progression, drug action and Parkinson's disease: why time cannot be ignored
    Nick Holford
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    Eur J Clin Pharmacol 64:207-16. 2008
  53. pmc Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study
    Steven A Gunzler
    Movement Disorders Center, Neurological Institute, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH 44106, USA
    Arch Neurol 65:193-8. 2008
    ..To determine whether low concentrations of a dopamine agonist worsen parkinsonism, which would suggest that activation of presynaptic dopamine autoreceptors causes a super-off state...
  54. ncbi request reprint Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
    Karen M Powers
    Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
    Mov Disord 23:88-95. 2008
    ..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated...
  55. pmc CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
    Jing Zhang
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Am J Clin Pathol 129:526-9. 2008
    ..This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD...
  56. ncbi request reprint GDNF in treatment of Parkinson's disease: response to editorial
    Anthony E Lang
    Lancet Neurol 5:200-2. 2006
  57. doi request reprint Exploring gene-environment interactions in Parkinson's disease
    Colin C McCulloch
    Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
    Hum Genet 123:257-65. 2008
    ..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk...
  58. ncbi request reprint Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics
    Denise M Kay
    Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
    Mov Disord 21:519-23. 2006
    ..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date...
  59. pmc Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study
    Alexis Elbaz
    INSERM, Unit 708, Paris, France
    Lancet Neurol 5:917-23. 2006
    ..Small-scale replication studies were largely non-confirmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain...
  60. pmc LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Am J Hum Genet 79:752-8. 2006
    ..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas...
  61. pmc Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease
    Carolyn M Hutter
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Eur J Neurol 15:134-9. 2008
    ..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease...
  62. pmc Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Ann Neurol 62:137-44. 2007
    ..We sought to replicate these findings...
  63. doi request reprint Genetic association between alpha-synuclein and idiopathic Parkinson's disease
    Denise M Kay
    New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008
    ..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD...

Research Grants21

  1. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 1999
    ..The major thrust for this grant period is to determine the contribution of the LDR to the benefits of levodopa treatment and to suggest methods to selectively induce or augment the LDR. ..
  2. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2007
    ....
  3. LEVODOPA PHARMACOKINETICS & PHARMACODYNAMICS
    John Nutt; Fiscal Year: 1991
    ..These experiments will help define factors which modify the response to levodopa as well as the phenomenon which underlie the development of the fluctuating response...
  4. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 1993
    ..5. Follow a small cohort of parkinsonian patients from the initiation of levodopa therapy to study the emergence of the "short" and "long" duration responses to levodopa as well as dyskinesia and "negative" levodopa actions...
  5. Levodopa Pharmacokinetca and Pharmacodynamics
    John Nutt; Fiscal Year: 2001
    ..abstract_text> ..
  6. Levodopa Pharmacokinetca and Pharmacodynamics
    John Nutt; Fiscal Year: 2002
    ..abstract_text> ..
  7. Levodopa Pharmacokinetca and Pharmacodynamics
    John Nutt; Fiscal Year: 2003
    ..abstract_text> ..
  8. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2005
    ....
  9. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2006
    ....
  10. LEVODOPA PHARMACOKINETICS & PHARMACODYNAMICS
    John Nutt; Fiscal Year: 1990
    ..These experiments will help define factors which modify the response to levodopa as well as the phenomenon which underlie the development of the fluctuating response...
  11. LEVODOPA PHARMACOKINETICS & PHARMACODYNAMICS
    John Nutt; Fiscal Year: 1992
    ..5. Follow a small cohort of parkinsonian patients from the initiation of levodopa therapy to study the emergence of the "short" and "long" duration responses to levodopa as well as dyskinesia and "negative" levodopa actions...